KA
BMY icon

Keene & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Keene & Associates’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$3.5M Buy
61,881
+326
+0.5% +$18.2K 2.81% 11
2024
Q3 		$3.18M Buy
61,555
+1,242
+2% +$58.3K 2.41% 22
2024
Q2 		$2.5M Buy
60,313
+1,249
+2% +$55.9K 2.04% 30
2024
Q1 		$3.2M Buy
59,064
+11,219
+23% +$572K 2.39% 27
2023
Q4 		$2.45M Buy
47,845
+140
+0.3% +$7.35K 2.04% 28
2023
Q3 		$2.77M Buy
47,705
+2,494
+6% +$153K 2.22% 26
2023
Q2 		$2.89M Buy
45,211
+435
+1% +$29.2K 2.25% 26
2023
Q1 		$3.1M Buy
44,776
+1,497
+3% +$106K 2.41% 23
2022
Q4 		$3.11M Sell
43,279
-3,301
-7% -$249K 2.78% 16
2022
Q3 		$3.31M Buy
46,580
+7
+0% +$508 3.04% 5
2022
Q2 		$3.59M Sell
46,573
-2,966
-6% -$226K 3.36% 3
2022
Q1 		$3.62M Buy
49,539
+2,040
+4% +$137K 2.95% 4
2021
Q4 		$2.96M Buy
+47,499
New +$2.79M 2.56% 17

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Keene & Associates's BMY Position: Q4 2024 in Review

Keene & Associates increased its Bristol-Myers Squibb (BMY) stake by 0.53% in Q4 2024, buying an estimated $18.2K and bringing the position to 61,881 shares worth $3.5M. The position accounts for 2.81% of the portfolio, ranked #11.

Keene & Associates first reported a position in BMY in Q4 2021 and has held it in 13 quarters since. The position peaked at $3.62M in Q1 2022. 2,486 funds tracked by Wall St. Rank hold BMY as of Q4 2024.

  • Keene & Associates held 61,881 shares of Bristol-Myers Squibb worth $3.5M as of Q4 2024.
  • Keene & Associates bought 326 Bristol-Myers Squibb shares in Q4 2024, an estimated $18.2K.
  • Bristol-Myers Squibb made up 2.81% of Keene & Associates's portfolio in Q4 2024, its #11 holding.
  • Keene & Associates first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 13 quarters since.
  • Keene & Associates's Bristol-Myers Squibb position peaked at $3.62M in Q1 2022.
  • 2,486 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2024.

Based on Keene & Associates's 13F filing for Q4 2024, filed 3 Feb 2025.